77 related articles for article (PubMed ID: 2377307)
1. [The ototoxicity of cisplatin in the chemotherapy of tumors of the head-neck area. Our experience].
Sbalzarini G; Malusardi G; Pandolfi C; Cerri A
Minerva Med; 1990 May; 81(5):403-5. PubMed ID: 2377307
[TBL] [Abstract][Full Text] [Related]
2. Hearing loss--risk factor for cisplatin ototoxicity? Observations.
Durrant JD; Rodgers G; Myers EN; Johnson JT
Am J Otol; 1990 Sep; 11(5):375-7. PubMed ID: 2240186
[TBL] [Abstract][Full Text] [Related]
3. [Combination cisplatin, 5-FU and low-dose radiotherapy in recurrent carcinomas of the head and neck].
Bolla M; Borgel J; Junien-Lavillauroy ; Sefi A; Guenons A; Lebeau J; Kolodie H; Vincent F
Bull Cancer; 1986; 73(5):542-4. PubMed ID: 3779135
[No Abstract] [Full Text] [Related]
4. [The ototoxicity of the cytostatic drug carboplatin in patients with head-neck tumors].
Bauer FP; Westhofen M; Kehrl W
Laryngorhinootologie; 1992 Aug; 71(8):412-5. PubMed ID: 1388466
[TBL] [Abstract][Full Text] [Related]
5. Alteration of chemotherapy (cisplatin and 5-FU) and radiotherapy in the management of advanced or recurrent head and neck cancer: a phase II study.
Grimaldi A; Merlano M; Benasso M; Margarino G; Scasso F; Corvò R; Rosso R
Chemioterapia; 1986 Oct; 5(5):356-9. PubMed ID: 3791484
[TBL] [Abstract][Full Text] [Related]
6. [Ototoxicity of cis-diammine glycolato platinum, 254-S].
Horiuchi M; Miyake H; Ota K
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1327-32. PubMed ID: 1503488
[TBL] [Abstract][Full Text] [Related]
7. [Prospects for using platinum coordination compounds possessing antitumor activity].
Sidorik EP; Burlaka AP; Sirdorik OA; Korchevaia LM
Eksp Onkol; 1984; 6(6):6-12. PubMed ID: 6396067
[TBL] [Abstract][Full Text] [Related]
8. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
9. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and 5-fluorouracil in recurrent head and neck cancer: results of an outpatient schedule.
Airoldi M; Pedani F; Brando V; Giordano C; Gabriele P
Chemioterapia; 1988 Apr; 7(2):127-9. PubMed ID: 3396116
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.
Sandler S; Bonomi P; Taylor B; Showel J; Slayton R; Lerner H
Cancer Treat Rep; 1984 Sep; 68(9):1163-5. PubMed ID: 6541095
[TBL] [Abstract][Full Text] [Related]
12. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
Baghi M; Hambek M; Wagenblast J; May A; Gstoettner W; Knecht R
Anticancer Res; 2006; 26(1B):585-90. PubMed ID: 16739325
[TBL] [Abstract][Full Text] [Related]
14. Decreased hearing after combined modality therapy for head and neck cancer.
Pearson SE; Meyer AC; Adams GL; Ondrey FG
Am J Otolaryngol; 2006; 27(2):76-80. PubMed ID: 16500467
[TBL] [Abstract][Full Text] [Related]
15. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
18. [Palliative antineoplastic chemotherapy of patients with head and neck tumors].
Kleemann D; Hingst V; Kramp B
HNO; 1994 May; 42(5):275-9. PubMed ID: 7519592
[TBL] [Abstract][Full Text] [Related]
19. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
20. Clinical phase I study of paclitaxel followed by cisplatin in advanced head and neck squamous cell carcinoma.
Hanauske AR; Schilling T; Heinrich B; Kau R; Herzog M; Quasthoff S; Bochtler H; Diergarten K; Rastetter J
Semin Oncol; 1995 Dec; 22(6 Suppl 14):35-9. PubMed ID: 8553082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
